In our Season 5 premiere, we dive into Alpha-1 Antitrypsin Deficiency (AATD) — a rare but serious genetic condition that affects both the lungs and liver. People with AATD have a deficiency in a protein (alpha-1 antitrypsin) that normally protects lung tissue from inflammation. Without enough of this protein, individuals are at higher risk of developing lung conditions such as COPD, often at a younger age and even without a history of smoking.

Despite being underdiagnosed and often misunderstood, AATD affects thousands of Canadians. Raising awareness, improving access to testing, and advocating for equitable treatment is critical — and that’s where this episode begins.

Our special guest:

We’re joined by Angela Diano, Executive Director of AlphaNet Canada, who brings both professional expertise and personal insight into what it means to live with a chronic condition. With decades of experience in patient advocacy, Angela has played a key role in expanding access to augmentation therapy, influencing national policy, and empowering patients to take an active role in their care.

Access free resources related to this episode: https://chroniclungdiseases.com/en/news/breaking-down-aatd

More about Season 5: https://chroniclungdiseases.com/en/the-expand-podcast-season-5-aatd/

This podcast series was developed with support from Takeda Canada. Together, we’re working to raise awareness and improve care for those living with Alpha-1 across the country.

#aatd #theexpandpodcast

Alpha-1 antitrypsin deficiency, lung disease, patient advocacy, augmentation therapy, healthcare access, chronic obstructive pulmonary disease, genetic conditions, awareness, diagnosis, treatment